IP Library Granted Patent US 9,006,340
Granted Patent B2
US 9,006,340 · App. 13/898,624 · Granted Apr 14, 2015

Lung volume reduction therapy using crosslinked non-natural polymers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,006,340
App. No.
13/898,624
Granted
Apr 14, 2015
Kind
B2
Abstract

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema.

Claims (61)

1. A method of attaching a first tissue to a second tissue of a patient in need thereof, comprising the step of applying to said first tissue or said second tissue or both an effective amount of a hydrogel, wherein said hydrogel is prepared from

a first non-natural polymer and a first cross-linker;

said first non-natural polymer consists essentially of a plurality of subunits independently selected from the group consisting of

wherein independently for each occurrence

X is —(C(R) 2 ) n —, —(CH 2 OCH 2 ) n CH 2 —, —(CH 2 ) n -(cycloalkyl)-(CH 2 ) n —, or —(CH 2 ) n -(aryl)-(CH 2 ) n —;

R is H or lower alkyl;

Y is —NHR′, —OH or —SH;

R′ is hydrogen, NH 2 , aliphatic, aromatic, heterocyclic, cycloaliphatic or a saturated heterocyclic moiety;

n is 1-20; and

about 60 mol % to about 99 mol % of the subunits are

and

said first cross-linker comprises at least two pendant first electrophilic groups,

thereby attaching said first tissue to said second tissue.

2. The method of claim 1 , wherein X is —(C(R) 2 ) n —; and R is H.

3. The method of claim 1 , wherein Y is NHR′; and R′ is H.

4. The method of claim 1 , wherein X is —(C(R) 2 ) n —; R is H; Y is NHR′; and R′ is H.

5. The method of claim 1 , wherein said first electrophilic groups are selected from the group consisting of aziridines, episulfides, cyclic sulfates, carbonates, imines, esters, lactones, halides, epoxides, hydroxysuccinimidyl esters, maleimides, iodoacetamides, phosphates, sulfates, sulfonates, ketones and aldehydes.

6. The method of claim 1 , wherein said first cross-linker is a polyaldehyde.

7. The method of claim 1 , wherein said first cross-linker is a dialdehyde.

8. The method of claim 1 , wherein said first cross-linker is glutaraldehyde.

9. The method of claim 1 , wherein said first cross-linker is represented by the following formula:

wherein independently for each occurrence

n is 0-12;

m is 0-12; and

Y is a di-radical of an aliphatic, cycloaliphatic, aromatic, heterocycloaliphatic or heterocyclic moiety.

10. The method of claim 1 , wherein said first cross-linker is represented by the following formula:

wherein independently for each occurrence

n is 0-12;

m is 0-12; and

R 4 and R 5 are each independently hydrogen, aliphatic, cycloaliphatic, aromatic, heterocycloaliphatic or heterocyclic moiety.

11. A method of attaching a first tissue to a second tissue of a patient in need thereof, comprising the step of applying to said first tissue or said second tissue or both an effective amount of a hydrogel, wherein said hydrogel is prepared from a second non-natural polymer and a second cross-linker;

said second non-natural polymer consists essentially of a plurality of subunits independently selected from the group consisting of

wherein independently for each occurrence

X is —(C(R) 2 ) n —, —(CH 2 OCH 2 ) n CH 2 —, —(CH 2 ) n -(cycloalkyl)-(CH 2 ) n —, or —(CH 2 ) n -(aryl)-(CH 2 ) n —;

R is H or lower alkyl;

Z is —C(O)R″, —C(S)R″, halide, —C(NR″)R″, —OP(O)(OR″) 2 , —OP(O)(OR″)(R″), —OS(O) 2 (OR″), or —OS(O) 2 R″;

R″ is hydrogen, aliphatic, aromatic or heterocyclic;

n is independently for each occurrence 1-20; and

about 60 mol % to about 99 mol % of the subunits are

and

said second cross-linker comprises at least two pendant second nucleophilic groups, thereby attaching said first tissue to said second tissue.

12. The method of claim 11 , wherein X is —(C(R) 2 ) n — and R is H.

13. The method of claim 11 , wherein Z is an aldehyde.

14. The method of claim 11 , wherein X is —(C(R) 2 ) n —; R is H; and Z is an aldehyde.

15. The method of claim 11 , wherein said second nucleophilic groups are selected from the group consisting of alcohols, amines, hydrazines, cyanides, or thiols.

16. The method of claim 11 , wherein said second cross-linker is a polyamine, polyalcohol or polythiol.

17. The method of claim 11 , wherein said second cross-linker is a diamine, dialcohol or dithiol.

18. The method of claim 11 , wherein said second cross-linker is represented by the following formula:

wherein independently for each occurrence

n is 0-12;

m is 0-12;

R 6 is selected from the group consisting of alcohols, amines, hydrazines, cyanides and thiols; and

Y is a di-radical of an aliphatic, cycloaliphatic, aromatic, heterocycloaliphatic or heterocyclic moiety.

19. The method of claim 11 , wherein said second cross-linker is represented by the following formula:

wherein independently for each occurrence

n is 0-12;

m is 0-12;

R 4 and R 5 are each independently hydrogen, aliphatic, cycloaliphatic, aromatic, heterocycloaliphatic or heterocyclic moiety; and

R 6 is selected from the group consisting of alcohols, amines, hydrazines, cyanides and thiols.

20. The method of claim 1 , wherein said hydrogel is introduced into a target region of the patient's lung.

21. The method of claim 11 , wherein said hydrogel is introduced into a target region of the patient's lung.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Mar 5, 2026
From: CANADIAN IMPERIAL BANK OF COMMERCE
To: PULMONX CORPORATION
Reel/Frame 073980/0673 →
SECURITY INTEREST Recorded Mar 2, 2026
From: PULMONX CORPORATION
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 075012/0453 →
SECURITY INTEREST Recorded Jan 27, 2026
From: PULMONX CORPORATION
To: CANADIAN IMPERIAL BANK OF COMMERCE
Reel/Frame 074570/0001 →
SECURITY INTEREST Recorded Nov 30, 2022
From: PULMONX CORPORATION
To: CANADIAN IMPERIAL BANK OF COMMERCE
Reel/Frame 061929/0750 →
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2020
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: PULMONX CORPORATION
Reel/Frame 053952/0044 →
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2020
From: BOSTON SCIENTIFIC CORPORATION
To: PULMONX CORPORATION
Reel/Frame 053953/0548 →
MERGER Recorded Apr 23, 2019
From: PULMONX
To: PULMONX CORPORATION
Reel/Frame 048964/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2019
From: AERIS THERAPEUTICS, LLC.
To: PULMONX
Reel/Frame 048682/0506 →
SECURITY INTEREST Recorded Jul 26, 2017
From: PULMONX CORPORATION
To: BOSTON SCIENTIFIC CORPORATION
Reel/Frame 043349/0725 →
SECURITY INTEREST Recorded May 15, 2017
From: PULMONX CORPORATION
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 042466/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2013
From: AERIS THERAPEUTICS, INC.
To: AERIS THERAPEUTICS, LLC
Reel/Frame 030766/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2013
From: INGENITO, EDWARD P.; KROM, JAMES A.; SCHWARTZ, ALEXANDER; TSAI, LARRY W.
To: AERIS THERAPEUTICS, INC.
Reel/Frame 030766/0138 →